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Abstract
Introduction: Young key populations, defined in this article as men who have sex with men, transgender persons, people
who sell sex and people who inject drugs, are at particularly high risk for HIV. Due to the often marginalized and sometimes
criminalized status of young people who identify as members of key populations, there is a need for HIV prevention packages
that account for the unique and challenging circumstances they face. Pre-exposure prophylaxis (PrEP) is likely to become an
important element of combination prevention for many young key populations.
Objective: In this paper, we discuss important challenges to HIV prevention among young key populations, identify key
components of a tailored combination prevention package for this population and examine the role of PrEP in these prevention
packages.
Methods: We conducted a comprehensive review of the evidence to date on prevention strategies, challenges to prevention and
combination prevention packages for young key populations. We focused specifically on the role of PrEP in these prevention
packages and on young people under the age of 24, and 18 in particular.
Results and discussion: Combination prevention packages that include effective, acceptable and scalable behavioural, structural
and biologic interventions are needed for all key populations to prevent new HIV infections. Interventions in these packages
should meaningfully involve beneficiaries in the design and implementation of the intervention, and take into account the con-
text in which the intervention is being delivered to thoughtfully address issues of stigma and discrimination. These interventions
will likely be most effective if implemented in conjunction with strategies to facilitate an enabling environment, including
increasing access to HIV testing and health services for PrEP and other prevention strategies, decriminalizing key populations’
practices, increasing access to prevention and care, reducing stigma and discrimination, and fostering community empowerment.
PrEP could offer a highly effective, time-limited primary prevention for young key populations if it is implemented in combination
with other programs to increase access to health services and encourage the reliable use of PrEP while at risk of HIV exposure.
Conclusions: Reductions in HIV incidence will only be achieved through the implementation of combinations of interventions
that include biomedical and behavioural interventions, as well as components that address social, economic and other structural
factors that influence HIV prevention and transmission.
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Introduction
Globally young people face a high burden of HIV infection. It is
estimated that 39% of new infections occur among adoles-
cents annually, and despite global declines in HIV mortality
among adults [1], HIV-related deaths among young people
increased by 50% between 2005 and 2012 [2]. Key popula-
tions, defined here as men who have sex with men (MSM),
transgender persons, sex workers and people who inject
drugs (PWID), experience a high burden of HIV infection and
incidence rates in both concentrated and generalized epi-
demic settings. It is estimated that up to 50% of new infec-
tions occur among key populations annually [2].
Young people (which we define as persons between 10
and 24) who fall under the umbrella term ‘‘key population’’
are at particularly high risk for HIV and may engage in over-
lapping risk behaviours, such as injecting drugs and selling
sex.While data are scarce on the size of adolescent key popu-
lations (defined as ages 1019 years), in areas of the world
where the epidemic is concentrated among key populations,
adolescents clearly face an increased burden. It is estimated
that 95% of new infections among adolescents in Asia are
among key populations (PWID, MSM and sex workers) [3]
and that 70% of all individuals who inject drugs are under the
age of 25 [4]. A number of studies have documented that
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many individuals who engage in sex work or injection drug
use began before the age of 18 [5,6]. Among MSM globally,
infection rates continue to increase in many settings [7]. HIV
incidence data from the United States highlight the crisis
of HIV among young MSM (YMSM); from 2008 to 2011, HIV
incidence for YMSM aged 1324 years increased 26% [8].
Due to this increased risk, multiple programmatic calls have
been issued to refocus prevention efforts on adolescent and
youth key populations. Reductions in HIV incidence will only
be achieved through the implementation of combinations of
interventions that include biomedical and behavioural inter-
ventions, as well as components that address social, econo-
mic and other structural factors that influence HIV prevention
and transmission [915]. Antiretroviral-based prevention, spe-
cifically pre-exposure prophylaxis (PrEP), is one biomedical
prevention approach that has recently shown great promise in
reducing risk of HIV acquisition [1620]. However, its effec-
tiveness in some adolescent key populations remains unclear.
In this article, we review the current evidence on pre-
vention strategies for young key populations and specific
challenges to HIV prevention unique to young key popula-
tions, describe what an effective and tailored combination
prevention package would look like for young key popula-
tions and discuss the role of PrEP as a potential component
of that prevention package.
Methods
We conducted a comprehensive review of the evidence to
date on prevention strategies, challenges to prevention and
combination prevention packages for young key populations.
We focused specifically on the role of PrEP in these preven-
tion packages for young key populations under the age of
24, and under the age of 18 in particular. We examined the
published literature by searching PubMED using the following
search terms: PrEP, MSM, IDU, PWID, Sex work and HIV
prevention. We also examined the works cited of published
articles. We identified ongoing studies of PrEP by examining
the AVAC database of ongoing and planned PrEP evaluation
studies, conference abstracts and the NIH Research Portfolio
Online Reporting Tools (RePORT). We did not utilize any
exclusion criteria; however, we focused our search on studies
or evaluations of PrEP among young [1824], key populations
(MSM, PWID and people who sell sex).
Results and discussion
Challenges to HIV prevention among young key
populations
Young key populations are at increased risk of HIV infection
compared to adults due to cognitive, contextual and struc-
tural factors that increase their vulnerability to peer pressure,
manipulation and exploitation or abuse by older people [21].
At the same time, young key populations are a heteroge-
neous group and the risk factors for HIV differ across young
key populations and vary by age and setting.
Young PWID
Young PWID face a number of challenges to HIV prevention.
PWID aged 1829 are more likely to inject daily than other
age groups [22], more likely to share syringes than other age
groups [22], less likely to use harm reduction and treatment
services, more likely to be reliant on older people for access
to drugs and injecting equipment, more likely to obtain
needles from unofficial sources, and less informed about
risks and their rights [23]. Female PWIDs frequently experi-
ence violence from intimate partners, police and sex trade
clients [24], as well as homelessness [25] and psychiatric co-
morbidities [26], which may act synergistically, increasing
their risk for HIV infection [23]. Young female PWID in parti-
cular may face unique risks for HIV, including mental health
disorders [27], and high suicide risk [28]. In addition, young
female injectors have higher injecting risk behaviours comp-
ared to young male injectors, including multiple sex partners
[29] and co-infection with HIV and HCV [30].
Despite existing evidence-based prevention tools for PWID
populations, including opioid substitution therapy (OST) [3134],
needle and syringe exchange programs (NSP) [31,35,36] and
HIV testing and counselling (HTC) [31,37], the epidemic among
PWID continues to accelerate in many settings [38] while the
proportion of youth who are PWID continues to increase [39].
Young MSM and transgender persons
Young MSM experience multiple life stressors and high levels
of victimization based on sexual identity that can lead to
engagement in higher sexual and drug use activities, and also
make practicing HIV prevention strategies challenging [4042].
Compared to their heterosexual peers, YMSM have been
found to have an increased risk of depressive symptoms,
anxiety disorders, suicidal ideation and attempts, and PTSD
[4345]. Some YMSM may experience homelessness or un-
stable housing as a result of being driven out of their family
homes. Further, YMSM face additional social challenges in
developing a positive self-identity due to stigmatization, dis-
crimination and homophobia. The challenges that place YMSM,
and in particular YMSM of colour, at risk for HIV infection also
impact their awareness, access to, and adherence to preven-
tion services, including PrEP [4650]. For instance, despite
routine testing recommendations, MSM who are younger
(B25 years), black, and/or have low income are less likely to
test or be aware that they are HIV-infected [5155]. These
challenges are magnified in areas where homosexuality is
criminalized.
Young transgender women are also at extremely high risk
of HIV infection due to multiple concurrent risk factors, includ-
ing substance use, sex work, depression, unstable housing,
discrimination, violence and victimization [5659]. Limited
access to gender-sensitive health services can also interfere
with HIV prevention efforts.
Young people who sell sex
Young people who sell sex also face challenges that put them
at greater risk of HIV when compared to adult sex workers.
These include a heightened risk of physical and sexual vio-
lence by clients and law enforcement agents [6063]. As a
result of exploitation by adults, young people who sell sex
may lack control over the frequency and location of where
they sell sex, and may be more likely to work on the streets
than adults [6467]. Young people who have been orphaned
or abandoned by their family face social and economic
marginalization; consequently, in many parts of the world,
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children living on the street sell sex as a survival strategy
[6870]. In addition, young people who sell sex use condoms
less consistently than adult sex workers due to lack of access
to condoms, poor negotiating skills and limited knowledge
of issues related to sexual and reproductive health. Young
people who sell sex also face stigma and discrimination,
which not only affects their ability to access services but may
also lead to low self-worth and self-stigmatization [71]. Young
people who sell sex may also be more difficult to reach with
services because initiation into sex work may be gradual and
thus they may not recognize themselves to be at risk.
Legal and structural barriers to HIV prevention
Across all young key populations, parental permission laws in
many settings poses an additional challenge for delivering
effective prevention packages to this age group because they
prevent minors from accessing prevention and care services
without the involvement of a parent. A recent survey by
UNAIDS found that over 33 countries in Africa have age based
criteria for HTC [72]. In addition, young people often do not
seek health services due to stigma associated with youth
attending HIV prevention services, and lack of youth friendli-
ness and confidentiality in many health settings [73]. These
structural barriers are even greater for young key populations
because their behaviours are stigmatized and illegal in many
settings, resulting in discrimination, marginalization, possible
legal consequences (such as imprisonment) and fear of pun-
ishment [3]. In countries where homosexuality is illegal, YMSM
who fear being outed by health workers may delay care. Laws
that classify sex work among people who are under 18 as
sexual exploitation (designed to protect minors involved in
the sex industry), may have the unintended consequence of
encouraging young women who sell sex to deny involvement
or avoid health services because of fear of being sent to state
institutions or suffering abuse and harassment by law en-
forcement [7480]. Laws requiring parental permission for
prevention services also fail to recognize that many adoles-
cents engaged in injecting drug use or selling sex do not live
with family or may be orphans.
Combination prevention packages for young key
populations
Combination prevention packages that include effective, ac-
ceptable and scalable behavioural, structural and biologic
interventions are needed for all key populations in order to
have the greatest impact on preventing new infections. This is
supported by mathematical modelling which has found that
existing structural and behavioural prevention approaches for
key populations could be further strengthened by combining
them with newer biomedical prevention interventions, such
as PrEP [915]. Combination prevention packages should aim
to achieve high coverage of HIV testing and knowledge of
HIV serostatus, parsimony in selecting evidence-based inter-
ventions, synergy such that the effect of a combination of
interventions is at least the sum of the parts, if not greater,
and intervention coverage, which is a function of access to,
utilization of, and high retention (see Table 1) [81]. Based on
recent guidelines from the WHO for HIV prevention, diag-
nosis, treatment and care for key populations, combination
prevention packages should also include the key health care
sector interventions as summarized in Table 2 and strive to
create an enabling environment. Among key populations,
interventions that meaningfully involve beneficiaries in the
design and implementation of the intervention, and take into
account the context in which the intervention is being deli-
vered to thoughtfully address issues of stigma and discrimina-
tion are most likely to be most effective.
PrEP as a potential component of combination
prevention packages
PrEP has recently emerged as a promising biomedical inter-
vention to prevent HIV infection [1620] (see Table 3). For
adolescent and young key populations, PrEP could offer a
highly effective, time-limited primary prevention if they can
access health services and are motivated to use PrEP while at
risk of HIV exposure. Although no PrEP efficacy trials comp-
leted to date exclusively recruited adolescents and young
persons, all the trials included persons between ages 18 and
24 (see Table 4 and Figure 1). Nonetheless, young key
population face unique challenges that may influence their
willingness to use and adhere to PrEP. Addressing these
Table 1. Principles of combination prevention
Principle Details
1. High coverage of HIV testing and knowledge of HIV
serostatus
HIV testing is the ‘‘gateway’’ to both the HIV treatment and prevention
cascades; HIV testing programs need to facilitate linkages to care and
prevention
2. Parsimony in selecting evidence-based interventions Scale, coverage, affordability and impact could be compromised with more
complex combination packages
3. Pilot work to determine the acceptability and feasibility of
scaling these interventions
Achieve high coverage by prioritizing the subset of the population most at risk
of HIV transmission or acquisition
4. Synergy such that the effect of a combination of
interventions is at least the sum of the parts, if not greater
Delivering non-overlapping and complimentary interventions to reduce HIV
infectiousness and susceptibility
5. Intervention coverage A function of access to the interventions, willingness of persons prioritized
based on risk to utilize the interventions, high retention in the prevention/
treatment cascade
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challenges will be key to the success of PrEP as an inter-
vention strategy in this vulnerable population.
Adherence to medications is known to be a significant
challenge for young people, [8891] and thus adherence to
PrEP must be an important focus of any intervention provid-
ing PrEP to this population [92]. Across all the PrEP trials,
there is robust evidence that PrEP has high effectiveness, but
this effectiveness is highly dependent on adherence [11,93].
Sub-analyses of existing trial data suggest that younger and
unmarried participants as well as those with highest beha-
vioural risk were the least likely to adhere to PrEP [17,20,94].
These results are in line with evidence from other medical
conditions, which have found that between 10 and 90% of
adolescents demonstrate inadequate adherence to therapy,
and those least likely to adhere are the most vulnerable
psychosocially [89,95,96]. Notably, all the PrEP trials had a
subset of persons who had consistent and sustained use of
PrEP, which ranged from 30% in the VOICE [94] and FEM-PrEP
[82] trials to 80% in the Partners PrEP Study [17].
Concerns about adherence to PrEP and subsequent drug-
resistance are particularly strong for PWID [97], whose barriers
to antiretroviral therapy (ART) adherence include interrup-
tions in care due to low social support, incarceration, and
compulsory detoxification and detention [98]. At the same
time, a recent meta-analysis revealed that PWID had compar-
able rates of ART adherence to non-drug using populations
[98] suggesting that these concerns may be unfounded.
There are limited data on adherence to ART among persons
who sell sex [99,100]. Some reports suggest that persons
who sell sex may be poorly adherent due to their social
instability, increased mobility and police harassment, but
there are also data suggesting that persons who sell sex can
adhere if properly supported. However, while we can learn
from studies on ART adherence, the barriers to adherence
may be quite different among HIV-negative PrEP users [101].
There is a critical need to understand the reasons for poor
PrEP adherence among young women, including sex workers
[102]. Several upcoming studies and demonstration projects
are examining the impact of different adherence counselling
programs and delivery mechanisms to improve PrEP adher-
ence among participants (see Table 5, Supplementary files).
The differential uptake and sustained use among popula-
tions enrolled in placebo-controlled PrEP efficacy trials in part
reflects population differences in terms of levels of uncer-
tainty and ambivalence about using antiretrovirals for pre-
vention, risk perception, concerns about side effects, stigma,
reactions of others, partner support, participation in a placebo-
controlled trial to obtain access to health care and other
services, and concerns about randomization to placebo or a
product of uncertain efficacy [103105]. Uptake and adher-
ence among participants in clinical trials who are randomized
to placebo or active product and counselled about unknown
efficacy may not predict uptake and adherence among at risk
participants who are offered open-label product and coun-
selled about known efficacy and the importance of adherence.
Encouragingly, two studies of daily and intermittent oral
PrEP among MSM were recently stopped early due to high
effectiveness: 1) the immediate daily oral PrEP arm in the
Table 2. Key components of a comprehensive prevention package
The WHO comprehensive package for prevention
Essential health sector interventions IDU Sex workers MSM
1. Comprehensive condom and lubrication
programming
ª ª ª
2. Harm reduction interventions for substance
use
Needle and syringe programs and opioid
substitution therapy
3. Behavioural interventions ª ª ª
4. HIV testing and counselling ª ª ª
5. HIV treatment and care ª ª ª
6. Sexual and reproductive health interventions ª ª ª
7. Prevention and management of co-infections
and other co-morbidities






Essential strategies for an enabling environment Examples
1. Supportive legislation, policy and financial
commitment




2. Addressing stigma and discrimination ª ª ª
3. Community empowerment ª
4. Addressing violence against people from key
populations
ª ª ª
PrEP plus adherence support ªa ªa ª
aNote that the WHO has currently only issued a strong recommendation for PrEP use among MSM. The WHO has made no recommendations
regarding PrEP among PWIDs and sex workers but has called for PrEP demonstration projects to assess how to implement PrEP as part of
comprehensive risk reduction services in these populations.
OST, opioid substitution therapy; NSP, needle and syringe exchange programs.
Pettifor A et al. Journal of the International AIDS Society 2015, 18(Suppl 1):19434
http://www.jiasociety.org/index.php/jias/article/view/19434 | http://dx.doi.org/10.7448/IAS.18.2.19434
11
Table 3. Completed PrEP studies among key populations and young people
































Blood plasma: TDF detected in 66% in TDF
group (overall); TDF detected in 39% among
participants who seroconverted; TDF detected












 TDF vaginal gel
(BAT24)
 Placebo
39% (95% CI: 6, 60%;
p0.017)
Monthly (applicator) count divided by number
of sex acts that month: 72.20% (all participants);
61.3% among women who did not seroconvert;












Stopped for futility Self-report: 95%
Pill count: 88%
Blood plasma: TVD detected in 26% at
beginning of infection window, 21% at end of
window and 15% at both visits among women
who seroconverted; TVD detected in 35% at
beginning of the infection window, 37% of
women at end of the window and 24% at both
visits among women who did not seroconvert
iPrEx [16]


















Self-reported pill use: 95%
Pill count of unused study product: 8995%
Blood plasma: TVD detected in 9% among
participants who seroconverted; TVD was
detected in 51% among participants who did
not seroconvert
iPrEx OLE [83]
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TDF






































































































Table 3 (Continued )

































TDF: 67% (95% CI: 44,
81%; pB0.001)







Blood plasma: TDF/TVD detected in 31% among
participants who seroconverted; TDF/TVD
detected in 82% among participants who did
not seroconvert
Project PrEPare (ATN 082) [84]
US (Baltimore, Boston, Chicago,

















 3MV with TVD
(N20)
 3MV with placebo
n/a - Feasibility and
acceptability study
Self-reported: 62% (range 4383%)
Blood plasma: 63.2% (week 4), 20% (week 24)
TDF2 (CDC 494) [19]
Botswana











62.2% (95% CI: 21.5,
83.4%; p0.03)
Pill count: 84.2% (TVG group)
Self-reported 3 days prior: 94.4% (TVD group)
Blood plasma: TVD detected in 50% among
participants who seroconverted; TVD detected
in 81% among participants who did not
seroconvert
US Safety study (CDC 4323) [85]
US (San Francisco, Atlanta,
Boston)




Phase II safety study
 TDF upon enrolment
 Placebo upon
enrolment
 TDF 9 months after
enrolment
 Placebo 9 months
after enrolment






































































































Table 3 (Continued )















(95% CI; p-value) Adherence











 TDF vaginal gel
 Placebo (pill)
 Placebo (gel)
Stopped for futility Self-report and pill/applicator count: 90%
Blood plasma: TVD detected in 29% in TVD
group (overall); TVD detected in 21% in TVD
group (525, single); TVD detected in 54% in
TVD group (25, married); TDF detected in
28% in oral TDF group; TDF detected in 23% in
TDF gel group
Willingness of PWID to use PrEP
in Ukraine [87]
Ukraine






53% stated they would
‘‘definitely’’ be willing to
use PrEP (based on a 4-
point Likert scale)
32.6% stated they would
‘‘probably’’ be willing to
use PrEP
n/a






































































































United Kingdom compared to the delayed PrEP arm in the
PROUD study [106], and 2) the intermittent, event-driven
dosing of Truvada arm compared to the placebo arm in France
and Quebec in the IPERGAY study [107]. The high effectiveness
demonstrated early in these studies indicate that adherence
to oral PrEP among MSM is high in the context of known
efficacy even when delivered with less intensive adherence
counselling.
In addition, new studies and ongoing demonstration
projects are examining new PrEP formulations and coitally-
dependent pill/gel-schedules, which may simplify and im-
prove adherence (see Table 5, Supplementary files). Long
acting injectable and slow release delivery mechanisms (for
example, using a vaginal ring) are currently being evaluated
for efficacy and may be available for more real world eva-
luation within the next 13 years. Antiretrovirals (including
dapivirine and tenofovir) are being formulated in sustained
release vaginal rings combined with levonorgestrol for con-
traception (multi-purpose technologies), which may further en-
hance uptake and adherence for young women [108,109].
These new PrEP delivery mechanisms are likely to be highly
applicable to adolescent key populations as they do not require
daily pill taking which may prove difficult for some adolescents,
particularly those with unpredictable lives, unstable living
situations, and/or mental health or substance use issues.
In sum, the efficacy of oral TDF and FTC/TDF has been
demonstrated across multiple studies, and demonstration
projects are currently evaluating strategies to improve access
to, uptake of and adherence to PrEP in key populations (see
Table 4 and Table 5 in Supplementary files). PrEP has great
promise if integrated into a combination prevention package
that provides support for the structural and behavioural
barriers to this innovative biomedical prevention strategy,
including accessing health care, assessing one’s risk and
motivation for prevention, and developing adherence habits.
Below we will highlight what an ideal combination package
Table 4. Overview of completed and ongoing PrEP studies targeting young people and key populations, by population and PrEP
type/mode of delivery
Target population Oral PrEP and combination prevention
Dosing/alternative
formulations of oral PrEP Topical PrEPc
Under 18 years old CHAMPS-SA Plus Pillsa
FACTS 002a
Project PrEPare (ATN 113)a
MSM/TGW California Collaborative
Treatment Group Consortium/ALERT (CCTG 593)
DemoPrEP
The Demo Project (NIAID)
East Bay Consortium/CRUSHb
HPTN 073
Los Angeles County PATH PrEP Demo Project
LVCT and SWOP
Project PrEPare (ATN 110)b




Sustainable Health Center Implementation PrEP







SW Durbar (DMSC) and Ashodaya Samithi
LVCT and SWOP
SAPPH-IRe
TAPS: Expanded use of ART for treatment and
prevention for female sex workers in South Africa
Wits Reproductive Health and HIV Institute
PWID Bangkok Tenofovir Study Open-Label Extension
Sustainable Health Center Implementation PrEP
Pilot Study (SHIPP) (CDC Foundation)
aParticipants 18 and younger.
bparticipants 24 and younger.
cnote that there are other efficacy trials of topical PrEP (e.g., FACTS 001, ASPIRE, Ring Study) but they do not exclusively target young people or
key populations.
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for young key populations might look like and the potential
role of PrEP within such a package.
Combination prevention for MSM and transgender
persons
An ideal combination prevention package for YMSM and
young transgendered persons would include effective inter-
ventions to address behavioural risk factors, PrEP uptake and
adherence support as well as addressing structural barriers to
prevention (including criminalization, stigma, discrimination
and homophobia). High rates of mobile phone ownership and
technology use among youth provide a unique platform to
deliver tailored, engaging HIV health promotion interventions
to YMSM and young transgendered persons [110112]. For
example, a combination prevention app could include fea-
tures to 1) increase HIV testing (e.g. provide youth with
access to nearby HIV testing locations or facilitate ordering of
home HIV tests); 2) help YMSM and young transgendered
persons successfully access and adhere to PrEP (e.g. tracking
of pill taking, side effects, pharmacy refill information); and
3) enhance patient provider interactions to ensure timely and
comprehensive follow-up (e.g. symptom tracker to document
any symptoms of acute HIV infection, reminders for HIV and
other testing). However, to date behavioural and structural
HIV prevention interventions designed specifically for YMSM
and young transgendered persons are severely lacking. A recent
review of primary HIV prevention interventions for adolescents/
young adults found that of the 92 articles reviewed, only three
unique interventions were specifically tailored to the needs of
gay/bisexual male adolescents and young adults [113].
Young transgender women may require a fairly different
package of combination HIV prevention interventions than
young MSM. Although they may share some similar structural
and social barriers, they face unique challenges, including
those related to transitioning, gender discrimination, trans-
phobia and violence [114]. A recent review has highlighted
the lack of evidence-based interventions for transgender
populations and the need to understand differences between
MSM and transgender populations and the heterogeneity
within the group so that prevention and care can be im-
plemented more effectively [115].
Currently two studies have been conducted that have
offered PrEP to younger MSM (Project PrEPare and iPrEx
OLE), while only one study has included transgender persons
(iPrEx OLE) [83,84] (see Table 3). Transgender persons have
been largely underrepresented in biomedical and behavioural
prevention trials and more work is needed to determine
the ideal set of interventions in a combination prevention
package for this population [114]. In contrast, in the two
years since the FDA approved Truvada for PrEP, there is
growing momentum in policy related to PrEP for MSM. CDC
guidance in 2014 made PrEP a central part of US prevention
efforts [116], and it has been featured as one of the three key
components of the New York state response to reduce new
HIV infections [117]. In 2014 WHO issued guidelines for PrEP
implementation which focused on MSM [118].
Project PrEPare was a pilot study conducted in the US that
used a randomized 3-arm design to compare an efficacious
behavioural HIV prevention intervention (Many Men, Many
Voices*3 MV) alone with 3 MV combined with PrEP
(tenofovir/emtricitabine), and 3 MV combined with placebo
[84]. For the purposes of this trial, the 3 MV intervention was
adapted for use with youth groups of mixed racial and ethnic
identities. Sixty-eight youth (mean age19.97 years; 53%
African American, 40% Latino) were enrolled, 58 were
randomized, 20 received PrEP and no one under the age of
18 was included [84]. Although acceptability (size of the FTC/
TDF pill) was an issue for some men, the study found that
Figure 1. Representation of key populations and young people included in completed PrEP studies.
Bangkok and TDF2 participants in ‘‘participants B25 category’’ includes participants under 30 years of age.
Number of participants in ‘‘participants B25’’ unknown for US Safety study and VOICE study.
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62% had tenofovir detected in plasma samples, which is an
encouraging finding in this age group, and likely could be
improved with an adherence support intervention during
PrEP use. Future PrEP demonstration projects among YMSM
should focus on acceptability, motivation and adherence
support for men who are motivated to take PrEP.
To date some of the structural barriers to uptake of PrEP
among YMSM have included cost of the medication and
the comprehensive services required for those on PrEP, and
limited access to primary care. Providers may also be not
offering PrEP to those most in need. To improve uptake of
PrEP, we recommend more fully integrating the provision of
PrEP into sexually transmitted infection (STI) services and
educating health care providers about the efficacy of PrEP
and strategies for providing culturally competent and non-
judgmental care for young key populations. We anticipate
that the provider reluctance to prescribe PrEP will decrease
in the wake of the PROUD and IPERGAY results, which indi-
cate that MSM were able to make informed decisions about
their risks and need for PrEP and adhere sufficiently to obtain
substantial prevention benefits.
Combination prevention for young people who sell sex
Combination prevention for HIV in young people who sell sex
should include behavioural, structural and biomedical inter-
ventions. Community empowerment, condom promotion,
HTC with linkage to treatment and care services, STI treat-
ment and health education have been shown to be effec-
tive interventions for sex workers, but they have not been
taken to scale or adequately resourced in most parts of the
world [9].
To be effective, interventions targeting young people who
sell sex must address their specific needs and the unique
barriers they face to accessing programs for adult sex workers.
For example, young sex workers may not perceive HIV pre-
vention programs to be relevant to them, and may face
competition from adult sex workers, who act as gatekeepers
to sex worker HIV prevention programs. Tailored programs for
younger women also need to encompass interventions that
address issues of social protection which can be implemented
as required on a case by case basis. Given that the majority of
sex workers who acquire HIV are infected early in their career,
programs need to have a strategy for identifying young people
shortly after they start selling sex, and to facilitate their timely
engagement with prevention services [119].
Access to prevention services is also often hampered by the
legal and policy environment. UNAIDS defines sex workers as
‘‘people who receive money or goods in exchange for sexual
services, either regularly or occasionally’’[120], while the Con-
vention on the Rights of the Child considers anyone selling sex
under age 18 years to be sexually exploited [71]. Governments
have a legal obligation to protect those under 18 from sexual
exploitation and this obligation frequently results in a ‘‘raid
and rescue’’ response to HIV prevention which perversely
results in increased vulnerability and decreased access to HIV
prevention services [121]. Criminalization of sex work in many
settings results in young people who sell sex being afraid
to seek services because of fear of arrest or imprisonment.
Some countries have mandatory reporting laws for people
under 18 selling sex which put health care providers in direct
conflict with their responsibility to provide confidential care [75].
Although there are examples of small scale HIV prevention
programs targeting young people who sell sex, these existing
approaches need to be scaled up more widely and evalua-
ted to realize improvements in HIV prevention and sexual
and reproductive health among this group. For example the
SHARPER project in Accra, Ghana effectively uses young peer
educators who are paired with older women in the com-
munity ‘‘peer protectors’’. The program focuses on health
education, skills building, assisting with linkage to services
and violence prevention [122]. In the Philippines, the River of
Life Initiative works with young MSM who sell sex and uses
peer to peer outreach to contact these hard to reach young
men [123].
To date, there have been no completed trials of PrEP
conducted specifically among sex workers (although two of
the six trials demonstrating efficacy included sex worker
participants, see Table 3). However, when the number needed
to treat (NNT) to avert one HIV infection was estimated
among sub-sets of women in the Partners PrEP trial, the NNT
was lowest among women under 30 years and women who
reported multiple high-risk behaviours. These findings sug-
gest that the number of young women who sell sex that
would need to access PrEP to prevent one infection is likely
to be favourable PrEP can be safely and effectively imple-
mented [124].
We know already that PrEP for young people who sell
sex should not be considered as a stand-alone intervention,
but will need to be implemented within a comprehensive
package of interventions that strengthen community cohesion
(such as those described in the examples above) alongside
behavioural/technological approaches to build individual
agency, self-efficacy and skills. The intervention components
will need to be relevant to, and address the specific concerns
of, young people who sell sex and be implemented in con-
junction with them. It is likely that the exact form and delivery
of comprehensive prevention will be context and culture
specific. The next step will be to use formative research to
develop and test comprehensive prevention packages for
young people who sell sex, which can then be rigorously
evaluated as they are scaled up using impact evaluation.
People who inject drugs
UNAIDS has identified nine interventions considered essen-
tial to prevent HIV among IDUs. These interventions consist
of needle syringe programs, opioid substitution treatment,
HTC, ART, STI treatment, condom distribution, information
and education campaigns, vaccination and treatment of viral
hepatitis, and prevention and treatment of tuberculosis [29].
In this context, PrEP is a promising addition to the existing
cadre of evidence-based interventions especially given that
tenofovir does not alter the pharmacokinetics or pharmaco-
dynamics of methadone or benprenorphine [125].
While evidence on PrEP among key populations is growing,
studies with empirical data collection among PWID are limited
to one PrEP efficacy trial among PWID (see Table 3). The
Bangkok Tenofovir Study which was a phase III randomized
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double-blind placebo-controlled trial to evaluate the efficacy
of PrEP with daily oral tenofovir on HIV infections in PWID [18].
Despite the promising results of the Bangkok Tenofovir
Study, some have questioned whether PrEP provided protec-
tion against parenteral HIV exposure, given the low and
declining incidence of reported injection and needle sharing
behaviours during the trial. Although it is not possible to
distinguish between the proportion of infections in the
Bangkok Tenofovir Study that were attributable to parenteral
versus sexual transmission [126], the key finding was the
halving of HIV incidence in the PrEP arm. This is a general-
izable result for HIV protection for PWIDs given that many
PWID populations are at risk of HIV through both parenteral
and sexual exposure. Notably, the majority of study partici-
pants were on methadone maintenance and in both arms,
and injecting risk behaviours, including injecting and needle
sharing decreased dramatically over three years of follow-up,
suggesting that parenteral transmission may have only
contributed a small proportion of the incidence. Thus, the
Bangkok Tenofovir Study demonstrates that daily oral teno-
fovir significantly reduces HIV transmission among PWID in
the context of opiate substitution therapy, and thus is a
demonstration of effective combination prevention for PWID.
Several challenges remain for implementing PrEP among
PWID outside a research setting. In many settings, injecting
drug use is highly stigmatized, and PWID-specific HIV pre-
vention interventions do not have adequate governmental
or public support [127,128] leading to suboptimal imple-
mentation of known highly effective prevention methods
[23,129]. Until these evidence-based intervention compo-
nents including NSP, OST and HTC are successfully imple-
mented, the role of PrEP may be limited. A recent systematic
review of barriers to treatment among PWID [93] found that
structural barriers, including incarceration, inadequate hous-
ing, and lack of a legal income [130,131], were more common
than individual-level barriers to accessing HIV treatment and
care. In order for PrEP to be successfully implemented, a
supportive political, social and environmental platform is
imperative.
PrEP is not a replacement for other evidence-based programs.
Rather, PrEP should be considered as part of a combination
prevention package that includes other proven prevention
strategies such as OST, NSP and HTC [23,31,34,129,132]. A
package that integrates and provides PrEP into drug treatment
programs and pharmacies and HTC clinics where there is the
ability to frequently perform HIV testing and create linkages to
providers to monitor patients would be ideal. In addition, it
will be important to package PrEP with interventions that have
been shown to increase adherence among PWID, particularly
when targeting adolescent PWID, such as directly observed
therapy and methadone maintenance therapy. Sub-populations
of adolescent PWID such as young injecting initiates are
more likely to be homeless [133] and engage in a range
of risk behaviours including hazardous alcohol use, cocaine
use, crystal methamphetamine use [133], unprotected sex
[134,135] and survival sex [133]. The concurrent high-risk
behaviour and lack of effective treatments for cocaine or
methamphetamine dependency underscore the importance
of PrEP in this population [129] while at the same time
highlighting their specific adherence challenges related to
alcohol use [136,137] and homelessness [138,139]. Beha-
vioural strategies that are part of a comprehensive approach
for young people should encourage the delay of sexual debut,
emphasize a reduction in the number of sexual partners and
encourage the use of voluntary HTC services without concern
for penalization. Further research is still needed to identify the
most effective combination of interventions for PWID with
an understanding that packages will need to be tailored for
specific settings and sub-populations of drug users, such as
adolescent and young PWID.
Conclusions
Effective yet scalable combination packages are needed for
young key populations. To date, adolescents generally, and
adolescent key populations specifically, have not been in-
cluded in studies of biomedical and combination prevention
due to regulatory and parental permission related issues
[140]. In an era of constrained resources, we need to identify
intervention components that are most effective at addres-
sing the key issues for the target population. In many settings,
young key populations are at highest risk of infection. While
the key populations highlighted in this paper face unique risks
for HIV, they also share many important challenges to pre-
vention, including stigma, marginalization, discrimination and,
in some cases, criminalization. It is critical that we address
these structural risk factors when developing prevention
packages for these populations.
With regard to PrEP as part of any combination prevention
package, the World Health Organization strongly recommends
the use of oral PrEP among MSM based on the evidence that
PrEP works in this population and is safe if taken as prescribed
[21]. Improving knowledge about PrEP, and uptake of and
adherence to this intervention among YMSM who have an
incredibly high incidence of infection is a priority. For young
PWID, expansion of harm reduction, specifically needle and
syringe programs, and OST is a critical first step to creating an
environment conducive to PrEP. Among sex workers, although
no PrEP trials to date have specifically targeted sex workers,
in particular young sex workers, PrEP has shown to be
efficacious in trials that included individuals who report
trading sex for money or housing. Structural impediments,
including policy/law, stigma and access to health service will
not be addressed by efficacy or behavioural trials, thus major
policy, educational and advocacy work will be needed along
with the prevention components discussed here. For all of
these populations, there is a need to address critical enablers
to access to HIV testing and health services for PrEP and other
prevention strategies, including decriminalization of key
populations’ practices, improved access to prevention and
care, a reduction in stigma and discrimination, and commu-
nity empowerment.
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